Literature DB >> 30587569

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.

William G Kerr1,2,3, John D Chisholm2.   

Abstract

After decades of intense effort, therapeutics that leverage the immune system to fight cancer have now been conclusively demonstrated to be effective. Immuno-oncology has arrived and will play a key role in the treatment of cancer for the foreseeable future. However, the search for novel methods to improve immune responses to cancer continues unabated. Toward this end, small molecules that can either reduce immune suppression in the tumor milieu or enhance activation of cytotoxic lymphocyte responses to the tumor are actively being pursued. Such novel treatment strategies might be used as monotherapies or combined with other cancer therapies to increase and broaden their efficacy. In this article, we provide an overview of small molecule immunotherapeutic approaches for the treatment of cancer. Over the next decade and beyond, these approaches could further enhance our ability to harness the immune system to combat cancer and thus become additional weapons in the oncologist's armory.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30587569      PMCID: PMC6330242          DOI: 10.4049/jimmunol.1800991

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  73 in total

1.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

2.  Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

Authors:  Gregory N Dietsch; Tressa D Randall; Raphael Gottardo; Donald W Northfelt; Ramesh K Ramanathan; Peter A Cohen; Kristi L Manjarrez; Mona Newkirk; James Kyle Bryan; Robert M Hershberg
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

3.  Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-04-14       Impact factor: 4.345

4.  Companies Scaling Back IDO1 Inhibitor Trials.

Authors: 
Journal:  Cancer Discov       Date:  2018-05-30       Impact factor: 39.397

5.  A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Authors:  Donald W Northfelt; Ramesh K Ramanathan; Peter A Cohen; Daniel D Von Hoff; Glen J Weiss; Gregory N Dietsch; Kristi L Manjarrez; Tressa D Randall; Robert M Hershberg
Journal:  Clin Cancer Res       Date:  2014-05-07       Impact factor: 12.531

6.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

7.  Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.

Authors:  Roger J Gillespie; Samantha J Bamford; Ruth Botting; Mike Comer; Sarah Denny; Suneel Gaur; Michael Griffin; Allan M Jordan; Anthony R Knight; Joanne Lerpiniere; Stefania Leonardi; Sean Lightowler; Steven McAteer; Angela Merrett; Anil Misra; Antony Padfield; Mark Reece; Mona Saadi; Daniel L Selwood; Gemma C Stratton; Dominic Surry; Richard Todd; Xin Tong; Vicki Ruston; Rebecca Upton; Scott M Weiss
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

8.  Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.

Authors:  A Suwa; T Yamamoto; A Sawada; K Minoura; N Hosogai; A Tahara; T Kurama; T Shimokawa; I Aramori
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

9.  First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

Authors:  Arkadiusz Z Dudek; Carla Yunis; Lester I Harrison; Sandeep Kumar; Ronald Hawkinson; Sarah Cooley; John P Vasilakos; Kevin S Gorski; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

10.  ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells.

Authors:  Weishan Huang; Sabrina Solouki; Nicholas Koylass; Song-Guo Zheng; Avery August
Journal:  Nat Commun       Date:  2017-06-21       Impact factor: 14.919

View more
  27 in total

Review 1.  Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.

Authors:  Thomas D Ryan; Rajaram Nagarajan; Justin Godown
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

2.  A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity.

Authors:  Serena Cortés-Kaplan; Reem Kurdieh; Mohamed S Hasim; Shelby Kaczmarek; Zaid Taha; Glib Maznyi; Scott McComb; Seung-Hwan Lee; Jean-Simon Diallo; Michele Ardolino
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

3.  Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells.

Authors:  Grace Lee; Sheela Karunanithi; Bruce Posner; Hanspeter Niederstrasser; Hong Cheng; Yuriy Federov; Shivaprasad Manjappa; Karam Musaitif; Huaiyu Wang; Zachary Jackson; David Wald
Journal:  Cancer Immunol Immunother       Date:  2021-11-23       Impact factor: 6.630

4.  Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.

Authors:  Priyanka Chauhan; Shuxian Hu; Sujata Prasad; Wen S Sheng; James R Lokensgard
Journal:  Glia       Date:  2020-10-31       Impact factor: 7.452

5.  Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells.

Authors:  Eden Kleiman; Gloria Sierra; Binchen Mao; Dennie Magcase; Marybeth V George; Pirouz M Daftarian
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

6.  Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.

Authors:  Wanzun Lin; Xianxin Qiu; Pian Sun; Yuling Ye; Qingting Huang; Lin Kong; Jiade J Lu
Journal:  Mol Ther Oncolytics       Date:  2021-04-29       Impact factor: 7.200

7.  Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Authors:  Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen
Journal:  Biomolecules       Date:  2021-05-10

8.  Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.

Authors:  Anna Aviñó; Anna Clua; Maria José Bleda; Ramon Eritja; Carme Fàbrega
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

9.  Biologically Active α-Amino Amide Analogs and γδ T Cells-A Unique Anticancer Approach for Leukemia.

Authors:  Ahmed Al Otaibi; Subuhi Sherwani; Salma Ahmed Al-Zahrani; Eida Mohammed Alshammari; Wahid Ali Khan; Abdulmohsen Khalaf D Alsukaibi; Shahper Nazeer Khan; Mohd Wajid Ali Khan
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 6.244

Review 10.  The role of small molecules in cell and gene therapy.

Authors:  Lewis L Brayshaw; Carlos Martinez-Fleites; Takis Athanasopoulos; Thomas Southgate; Laurent Jespers; Christopher Herring
Journal:  RSC Med Chem       Date:  2020-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.